Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SG301 SC Injection in Patients With Systemic Lupus Erythematosus

NCT07447986 is registered in ClinicalTrials.gov with Hangzhou Sumgen Biotech Co., Ltd. as lead sponsor.

NCT NCT07447986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07447986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SG301 SC Injection in Patients With Systemic Lupus Erythematosus
Lead sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
March 26, 2026
Completion date
December 31, 2027
Enrollment
120 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus (sle)